Spotlight on comorbidities in STEMI patients

Mortality for myocardial infarction is at its lowest historical level for 20 years, but comorbidities such as anemia, renal failure and hyperglycemia seem the next frontier to investigate their impact as risk modifiers mortality in acute myocardial infarction. Stress hyperglycemia is a very frequent...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruno, Raphael Romano, Kelm, Malte, Jung, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947710/
https://www.ncbi.nlm.nih.gov/pubmed/31922029
http://dx.doi.org/10.1002/edm2.102
_version_ 1783485611083038720
author Bruno, Raphael Romano
Kelm, Malte
Jung, Christian
author_facet Bruno, Raphael Romano
Kelm, Malte
Jung, Christian
author_sort Bruno, Raphael Romano
collection PubMed
description Mortality for myocardial infarction is at its lowest historical level for 20 years, but comorbidities such as anemia, renal failure and hyperglycemia seem the next frontier to investigate their impact as risk modifiers mortality in acute myocardial infarction. Stress hyperglycemia is a very frequent problem in STEMI, but continuous insulin infusion therapy (CIIT) resulted in >threefold and >twofold increased risks in‐hospital and 1‐year mortality, respectively.[Image: see text]
format Online
Article
Text
id pubmed-6947710
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69477102020-01-09 Spotlight on comorbidities in STEMI patients Bruno, Raphael Romano Kelm, Malte Jung, Christian Endocrinol Diabetes Metab Editorial Mortality for myocardial infarction is at its lowest historical level for 20 years, but comorbidities such as anemia, renal failure and hyperglycemia seem the next frontier to investigate their impact as risk modifiers mortality in acute myocardial infarction. Stress hyperglycemia is a very frequent problem in STEMI, but continuous insulin infusion therapy (CIIT) resulted in >threefold and >twofold increased risks in‐hospital and 1‐year mortality, respectively.[Image: see text] John Wiley and Sons Inc. 2019-11-19 /pmc/articles/PMC6947710/ /pubmed/31922029 http://dx.doi.org/10.1002/edm2.102 Text en © 2019 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Editorial
Bruno, Raphael Romano
Kelm, Malte
Jung, Christian
Spotlight on comorbidities in STEMI patients
title Spotlight on comorbidities in STEMI patients
title_full Spotlight on comorbidities in STEMI patients
title_fullStr Spotlight on comorbidities in STEMI patients
title_full_unstemmed Spotlight on comorbidities in STEMI patients
title_short Spotlight on comorbidities in STEMI patients
title_sort spotlight on comorbidities in stemi patients
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947710/
https://www.ncbi.nlm.nih.gov/pubmed/31922029
http://dx.doi.org/10.1002/edm2.102
work_keys_str_mv AT brunoraphaelromano spotlightoncomorbiditiesinstemipatients
AT kelmmalte spotlightoncomorbiditiesinstemipatients
AT jungchristian spotlightoncomorbiditiesinstemipatients

Ejemplares similares